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Background: Chronic inflammation may mediate risk of colorectal cancer (CRC); however, the association between circulating
inflammatory markers and risk of CRC has been inconsistent.
Methods: We prospectively evaluated the association of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and the soluble
tumour necrosis factor receptor 2 (sTNFR-2) with incident CRC among 274 cases and 532 matched controls nested in the Health
Professionals Follow-up Study.
Results: Multivariate relative risk (RR) of CRC comparing the extreme quartiles of plasma IL-6 was 1.54 (95% confidence interval
(CI), 0.99–2.40; Ptrend¼0.02). However, after excluding cases diagnosed within 2 years of blood draw, this association was not
statistically significant (RR¼1.26, 95% CI, 0.78–2.05; Ptrend¼0.21). In analyses restricted to cases diagnosed at least 2 years after
blood draw, the association of IL-6 with CRC appeared to differ by body mass index such that the significantly positive association
was only present among lean individuals (Pinteraction¼0.03). We did not observe any significant association between CRP or sTNFR-
2 and CRC.
Conclusion: Plasma inflammatory markers are not generally associated with risk of CRC among men. However, the possibility that
plasma IL-6 is associated with increased risk of CRC among lean men requires further investigation.
Chronic inflammation has an important role in colorectal cancer
(CRC). Patients with inflammatory bowel disease have a 2- to
3-fold greater lifetime risk of developing CRC (Bernstein et al,
2001). Conversely, regular, long-term aspirin and nonsteroidal
anti-inflammatory drug (NSAID) use has been shown to reduce
CRC risk by 30–40% (Flossmann and Rothwell, 2007). Recent
evidence also shows that chronic inflammation may partially
underlie the causal link between obesity and colorectal neoplasia
(Kant and Hull, 2011). Chronic inflammatory responses promote
carcinogenesis by inducing DNA damage, suppressing DNA repair,
stimulating angiogenesis and cell proliferation, and inhibiting
apoptosis (Coussens and Werb, 2002).
Circulating inflammatory proteins, such as C-reactive protein
(CRP), interleukin-6 (also known as IL-6) and tumour necrosis
factor (TNF)-a, are frequently used as biomarkers of chronic
inflammation and may mediate the inflammatory response (Libby
and Ridker, 2004; Hussain and Harris, 2007). However, because
inflammation is a component of the host response to cancer
(Coussens and Werb, 2002), elevated inflammatory markers may
result from occult cancer or a premalignant state rather than having
a causal role in carcinogenesis (Allin and Nordestgaard, 2011).
Data on the association between baseline circulating inflamma-
tory markers and risk of CRC has been inconsistent. Among 12
prospective studies, 5 showed a significant association between
CRP and CRC (Erlinger et al, 2004; Il’yasova et al, 2005; Gunter
et al, 2006; Otani et al, 2006; Aleksandrova et al, 2010), whereas the
remaining studies reported generally null (Ito et al, 2005; Siemes
et al, 2006; Trichopoulos et al, 2006; Allin et al, 2009; Heikkila et al,
2009; Chan et al, 2011) or even inverse associations (Zhang et al,
2005). The few studies examining IL-6 have not observed strong
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www.bjcancer.com|DOI:10.1038/bjc.2013.172 1891relationships (Il’yasova et al, 2005; Heikkila et al, 2009; Chan et al,
2011; Ho et al, 2012). We recently reported plasma soluble tumour
necrosis factor receptor 2 (sTNFR-2, also known as TNF receptor
superfamily member 1B, TNFRSF1B), a surrogate marker for
TNF-a (Diez-Ruiz et al, 1995; Pai et al, 2004), was significantly
associated with increased risk of CRC in women (Chan et al, 2011),
whereas other studies did not find any association between TNF-a
and CRC in an elderly population (Il’yasova et al, 2005) or in
postmenopausal women (Ho et al, 2012).
To extend these findings, we conducted a nested case-control
study within the Health Professionals Follow-up Study (HPFS) to
investigate the relationship of these plasma inflammatory markers
with incidence of CRC among men over 13–15 years of follow-up.
As these men have also provided detailed data on a range of
exposures associated with inflammation, we also had the unique
opportunity to prospectively evaluate the relationship between
levels of inflammatory markers in relation to these lifestyle factors
and risk of CRC.
MATERIALS AND METHODS
Study population. The HPFS is an ongoing prospective cohort
that includes 51529 US male health professionals, aged 40–75
years at enrolment, who returned a detailed survey about their
lifestyle, medication use, medical diagnoses, and a semiquantitative
food frequency questionnaire (FFQ) in 1986. With a follow-up rate
exceeding 90%, men have returned biennial questionnaires to
update lifestyle information and medical diagnoses; dietary
information is updated every 4 years. More details regarding the
main HPFS cohort have been published elsewhere (Rimm et al,
1991; Giovannucci et al, 1994). We requested written permission to
acquire medical records and pathological reports from men who
reported CRC. We identified deaths with over 96% sensitivity
through the National Death Index and next-of-kin (Stampfer et al,
1984). For all deaths, we requested permission from next-of-kin to
review medical records. A study physician, blinded to exposure
information, reviewed records to confirm cases of CRC and to
extract information on histological type, anatomic location, and
stage of the cancer (Greene et al, 2002).
Between 1993 and 1995, 18225 men returned a blood specimen
on ice packs by overnight courier. Upon receipt, blood samples
were immediately centrifuged, aliquoted into plasma, and stored in
continuously monitored liquid nitrogen freezers ( 1301Co r
below). More than 95% of samples arrived in our laboratory within
24h of collection. Among these men who provided a plasma
sample, we confirmed 287 incident CRC cases diagnosed between
the date of blood draw and 1 January 2008. Using risk set sampling,
we randomly selected two controls for each case matched on age
(within 2 years) and month per year of blood donation from eligible
participants who were alive and free of cancer (except for non-
melanoma skin cancer) at the time of diagnosis of the case. We
excluded 13 cases that failed laboratory assays. Among remaining
cases, 16 were matched to only one control. Thus, a total of 274 case
and 532 control participants were included in our analysis. This
study was approved by the Human Subjects Committee of the
Harvard School of Public Health and the Committee on the Use of
Human Subjects in Research at the Brigham and Women’s
Hospital, and all participants provided informed consent upon
return of the questionnaires and blood specimens.
Laboratory assays. In a core laboratory facility, we used a highly
sensitive immunoturbidimetric assay (Denka Seiken Co, Tokyo,
Japan) to measure CRP levels, an ultra-sensitive enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, MN, USA) to
measure IL-6, and an enzyme-linked immunosorbent assay (R&D
Systems) to measure sTNFR-2 levels. To examine the stability of
plasma biomarkers according to our storage techniques, we
previously compared the concentrations in samples taken from 17
female volunteers, which were processed and plasma frozen
immediately after venipuncture (the standard processing methods),
with samples that were stored as heparinised whole blood for
24–36h before processing (mimicking our collection conditions).
The mean IL-6, CRP, and sTNFR-2 values were almost identical and
the intraclass correlations between results of the two collection
methods were 0.99 for CRP, 0.93 for IL-6, and 0.91 for sTNFR-2,
demonstrating that our collection methods did not adversely affect
sample integrity (Pai et al, 2002; Chan et al, 2011). Samples from
case patients and their matched control participants were analysed
in the same batch. Quality control samples were randomly
interspersed among the case-control samples. Personnel blinded to
quality-control and case-control status conducted all assays.
Interleukin-6 and sTNFR-2 were assayed in a single run, whereas
CRP was measured in two batches over 6 years, and drift samples
were included to assess laboratory drift over time. The intraclass
correlation between results of the two drift batches was 0.9998,
suggesting the extraordinary stability of plasma CRP over time. The
intra-assay coefficients of variation from blinded quality control
samples were 7.8% for CRP, 12.1% for IL-6, and 10.1% for sTNFR-2.
Questionnaire and dietary information. As in previous analyses
(Chan et al, 2011), we used information collected from each
biennial questionnaire on weight, multivitamin use, aspirin use,
NSAID use, smoking, and endoscopic screening. Physical activity
was calculated by summing the products of time spent on a variety
of recreational or leisure-time activities with the average metabolic
equivalent (MET) for that activity (Chasan-Taber et al, 1996).
Dietary information was obtained from the 1986, 1990, and 1994
FFQs, and nutrient intake was adjusted for total energy consump-
tion using the residual method (Willett et al, 1997). Family history
of CRC was collected on the 1986, 1990, and 1992 questionnaires.
In 1987, B65% of participants provided measurements of hip and
waist circumferences after receiving a supplementary question-
naire, which included a tape measure and illustrated instructions.
We have previously shown that these self-reported measurements
in our cohort compared with technician measurements are
reasonably accurate (Pearson’s correlation coefficient: for weight,
r¼0.97; for waist circumference, r¼0.95; for hip circumference,
r¼0.88; for waist-to-hip ratio, r¼0.69) (Rimm et al, 1990).
Statistical analysis. We compared means (±s.d.) with medians
(±interquartile ranges) of continuous variables for case and
control participants using paired t test and Wilcoxon-signed rank
test, respectively. We used the conditional logistic regression to
compare categorical variables.
We employed multivariate linear models to assess the associa-
tions between lifestyle factors and plasma biomarker levels. The
logarithmic transformation of biomarker measurements was
conducted to fit the normal assumption of the model. We also
added a quadratic term of each continuous covariate to test for the
possible nonlinear relationship with biomarkers, and the test for
nonlinearity was not statistically significant. Therefore, we report
results from models without quadratic terms.
We calculated quartile cutpoints for plasma inflammatory
markers based on the distribution among control participants.
Relative risks (RRs) and corresponding 95% confidence intervals
(CIs) were estimated to assess associations between quartiles of
biomarker levels and CRC using conditional logistic regression.
Tests for trend were conducted using the median values for each
quartile of each plasma biomarker as a continuous variable in the
regression models. We also performed restricted cubic spline
analysis to examine for a possible nonlinear relationship between
each plasma inflammatory marker and CRC risk (Durrleman and
Simon, 1989). We used stepwise selection to determine knots
(Po0.05 for both stay and entry in the model) and tested for
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with only the linear term to the model with the linear and the cubic
spline terms.
In multivariate models, we additionally adjusted for family
history of CRC, history of endoscopic screening, body mass index
(BMI), physical activity (in MET-hours per week), pack-years of
smoking, alcohol consumption, regular aspirin/NSAID use, regular
use of multivitamins, red meat intake, and energy-adjusted daily
intake of folate, calcium and total fibre. To better approximate
long-term lifestyle and nutritional status in our analyses, we used
cumulative average BMI, physical activity, aspirin/NSAID use and
dietary intake variables derived from all biennial questionnaires
beginning in 1986 through the time of blood collection. Missing
information on a questionnaire was carried forward from available
information on prior questionnaires.
To evaluate whether observed associations varied by risk factors
for CRC, we conducted stratified analyses using unconditional
logistic regression, additionally adjusting for the matching factors
(that is, age and date of blood draw) in our multivariate models. To
test for multiplicative interaction between stratification factors and
biomarkers, we included cross-product terms for stratification
factors and biomarkers to our models.
We also examined the possible heterogeneity in the associations
between inflammatory markers and CRC, according to cancer
subsite (proximal colon, distal colon, or rectum) and stage (I, II, III,
or IV). A polytomous logistic regression model was used in which
the association with biomarkers was allowed to vary between the
case groups, but all the covariates were held constant. To calculate
P difference between case groups, we performed a likelihood ratio
test comparing the model described above with a model in which
all the associations were held constant between case groups.
For sensitivity analyses, we used the extreme studentised deviate
Many-Outlier procedure to identify outliers in each set of laboratory
results (Rosner, 1983), and repeated above analyses after excluding
outliers. We used SAS version 9.2 (SAS Institute, Inc, Cary, NC,
USA) for all analyses with the exception of the polytomous logistic
regression model, for which we used Stata version 11.0 (StataCorp,
College Station, TX, USA). All statistical tests were two sided and
Po0.05 was considered statistically significant.
RESULTS
Table 1 shows baseline characteristics of 274 CRC cases and 532
matched control participants. Overall, CRC cases were more likely
to be obese and have family history of CRC, whereas control
participants were more likely to have history of endoscopic
screening. The median values of plasma CRP were 1.36mgl
 1 in
cases and 1.11mgl
 1 in controls. For IL-6, the corresponding
median values were 1.60pgml
 1 among cases and 1.39pgml
 1
among controls. For sTNFR-2, the corresponding median values
were 2746pgml
 1 among cases and 2725pgml
 1 among
controls. None of the three biomarkers appeared to significantly
differ between cases and controls (for CRP, P¼0.72; for IL-6,
P¼0.42; for sTNFR-2, P¼0.28). The three markers were
significantly correlated (Spearman’s correlation coefficient: for
CRP and IL-6, r¼0.50; for CRP and sTNFR-2, r¼0.27; for IL-6
and sTNFR-2, r¼0.32; all P valueso0.001).
We examined the multivariate-adjusted associations of key
lifestyle factors with plasma inflammatory markers among control
participants. As shown in Table 2, age, obesity, and smoking were
positively associated with high levels of CRP, IL-6, and sTNFR-2.
Abdominal adiposity as measured by waist circumference appeared
to be more strongly associated with inflammatory markers than
BMI. Physical activity was inversely associated with inflammatory
marker levels, although only the association with sTNFR-2 attained
statistical significance (P¼0.03). Alcohol consumption was not
significantly associated with inflammatory markers. Compared
with non-users, regular users of aspirin or NSAIDs had higher
levels of inflammatory cytokines.
Table 3 shows the relationship between quartiles of plasma
inflammatory markers and risk of CRC. In unadjusted analyses,
both CRP and IL-6 were significantly associated with increased risk
Table 1. Baseline characteristics of study participants
Baseline
characteristics
Cases
(n¼274)
Controls
(n¼532) P-value
Mean age at blood draw
(s.d.), year
65.8 (8.3) 65.9 (8.3) 0.29
Non-white, no. (%) 17 (6.2) 31 (5.8) 0.83
CRC in a parent or
sibling, no. (%)
54 (19.7) 73 (13.7) 0.03
History of previous
endoscopy, no. (%)
154 (56.2) 358 (67.3) 0.002
Current multivitamin
use, no. (%)
130 (47.5) 275 (51.7) 0.25
Regular aspirin use,
no. (%)
a
115 (42.0) 258 (48.5) 0.08
Regular NSAID use,
no. (%)
b
31 (11.3) 63 (11.8) 0.82
Current or past smoker,
no. (%)
c
152 (57.6) 273 (54.0) 0.34
Mean pack-years of
smoking (s.d.)
d
24.6 (17.9) 24.8 (18.9) 0.72
Mean BMI (s.d.), kgm
 2 26.2 (3.1) 25.3 (2.7) o0.001
Mean waist
circumference (s.d.),
inch
e
38.6 (3.5) 37.5 (3.3) o0.001
Mean waist-to-hip ratio
(s.d.)
e
0.96 (0.05) 0.94 (0.05) o0.001
Mean MET-hours (s.d.) 31.9 (26.9) 30.9 (25.1) 0.60
Mean daily intakes (s.d.)
f
Alcohol, g 12.2 (14.8) 11.9 (14.7) 0.77
Folate, mg 494 (209) 520 (228) 0.13
Calcium, mg 917 (385) 928 (343) 0.62
Red meat, servings 1.15 (0.77) 1.08 (0.69) 0.17
Total fiber, g 22.1 (6.4) 22.6 (6.5) 0.23
Median CRP (IQR),
mgl
 1
1.36 (0.68–2.62) 1.11 (0.59–2.18) 0.72
Median IL-6 (IQR),
pgml
 1
1.60 (0.99–2.65) 1.39 (0.93–2.24) 0.42
Median sTNFR-2 (IQR),
pgml
 1
2746 (2346–3232) 2725 (2345–3336) 0.28
Abbreviations: BMI¼body mass index; CRC¼colorectal cancer; CRP¼C-reactive protein;
IL-6¼interleukin-6; IQR¼inter-quartile range; MET¼metabolic equivalent¼(caloric need
per kilogram body weight per hour activity)/(caloric need per kilogram body weight per
hour at rest); NSAID¼non-steroidal anti-inflammatory drug; sTNFR-2¼soluble tumour
necrosis factor receptor 2.
aA standard tablet contains 325mg aspirin, and regular users were defined as those who
used at least two tablets per week.
bRegular users were defined as those who used at least two tablets per week.
cThirty six participants with missing values were excluded from calculation.
dNever smokers (N¼345) and participants with missing values (N¼45) were excluded when
calculating means and s.d.
eMeasured in 1987, and 147 and 149 participants with missing information on waist
circumference and waist-to-hip ratio were excluded from calculation of means and s.d.,
respectively.
fFor dietary factors, up to 12 participants have missing information.
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factors, the magnitude of risk estimates were attenuated, and only
IL-6 remained significantly associated with increased risk of CRC
(Ptrend¼0.02). Compared with men in the lowest quartile (Q1),
men in the highest quartile (Q4) of plasma IL-6 had a multivariate
RR of 1.54 (95% CI, 0.99–2.40). There was no association
comparing extreme quartiles of CRP or sTNFR-2.
To assess the potential influence of subclinical neoplasia on
circulating marker levels, we further stratified the analysis according
to the follow-up time (within 2 years compared with after 2 years of
blood draw, Table 3). Comparing extreme quartiles, we observed
significant associations of CRP and IL-6 levels with CRC diagnosed
within 2 years of blood draw (for CRP, Ptrend¼0.005; for IL-6,
Ptrend¼0.01). In contrast, there was no significant association
between CRP, IL-6, or sTNFR-2 and risk of CRC among case
patients diagnosed after 2 years of follow-up (for CRP, Ptrend¼0.91;
for IL-6, Ptrend¼0.21; for sTNFR-2, Ptrend¼0.83). We also
examined the possibility of a nonlinear relation between each
plasma marker and risk of CRC using restricted cubic splines after
excluding cases diagnosed within 2 years of follow-up. We did not
find any nonlinear association for each marker (Supplementary
Figures S1–3). We further excluded cases diagnosed within 6 years
after blood collection, and the results did not materially change (for
CRP, multivariate RR¼0.61, 95% CI, 0.30–1.23, Ptrend¼0.32; for
IL-6, multivariate RR¼1.32, 95% CI, 0.74–2.37, Ptrend¼0.22; for
sTNFR-2, multivariate RR¼0.74, 95% CI, 0.37–1.49, Ptrend¼0.44).
Thus, we excluded cases diagnosed within 2 years of follow-up for
all subsequent analyses.
We then performed analyses of plasma inflammatory markers
according to selected subgroups, including age at the time of blood
collection, smoking, BMI, waist circumference, waist-to-hip ratio,
physical activity, regular aspirin/NSAID use, and cancer subsite and
stage. As shown in Table 4, the association of IL-6 with risk of CRC
appeared significantly stronger in lean men (BMI o25kgm
 2)
than in men who were overweight or obese (BMI X25kg/m
2;
Pinteraction¼0.03). Among men with BMI o25kgm
 2, men with
high IL-6 levels (Xmedian) had a significantly increased risk of
CRC relative to men with low IL-6 levels (omedian; multivariate
RR¼1.76, 95% CI¼1.04–2.98). In contrast, among men with
BMI X25kgm
 2, a nonsignificant inverse association was found
between high IL-6 levels and cancer risk (multivariate RR¼0.74,
95% CI, 0.47–1.18). No significant interaction was identified for
age, physical activity, or regular aspirin/NSAID use with inflam-
matory markers in relation to CRC risk. We also did not observe
significant difference in the associations between markers and CRC
risk according to subsite or stage (all P dif 40.05).
In sensitivity analysis, we additionally adjusted for race and time
of the day when the blood sample was collected in our multivariate
model, and the results remained essentially unchanged. We also
repeated our analyses after excluding participants with outliers in
laboratory measurements, or participants with history of coronary
heart disease or diabetes mellitus. The results were not materially
altered (data not shown).
DISCUSSION
In this prospective study of men, we showed that the significant
associations between plasma CRP, IL-6 levels, and risk of CRC
were restricted to cases diagnosed within 2 years of blood
collection. After excluding cases that occurred within 2 years of
follow-up, CRP, IL-6, or sTNFR-2 was not significantly associated
with subsequent development of CRC.
Our results are supported by the findings of several large
prospective studies that did not find any significant association
between baseline circulating CRP (Ito et al, 2005; Zhang et al, 2005;
Siemes et al, 2006; Trichopoulos et al, 2006; Allin et al, 2009;
Heikkila et al, 2009; Chan et al, 2011), IL-6 (Il’yasova et al, 2005;
Heikkila et al, 2009; Chan et al, 2011; Ho et al, 2012) or TNF-a
(Il’yasova et al, 2005; Ho et al, 2012) levels and risk of CRC. In
addition, a recent study that used instrumental variable analysis
(Mendelian randomisation) also did not observe an association
between either plasma CRP or genetically determined CRP levels
and risk of CRC (Allin et al, 2010). A separate study demonstrated
similar results in a large population (Siemes et al, 2006).
Our results differ from previous prospective studies that have
shown significant associations of various inflammatory markers
Table 2. Multivariate associations of lifestyle factors with levels of plasma inflammatory markers among control participants
a
CRP (mgl 1) IL-6 (pgml 1) sTNFR-2 (pgml 1)
Variable
Relative change
(%)
b P-value
Relative change
(%)
b P-value
Relative change
(%)
b P-value
Age, year 16.8 o0.001 18.3 o0.001 9.8 o0.001
BMI, kgm
 2 16.1 o0.001 4.8 0.11 1.7 0.13
Waist circumference, inch
c 21.2 o0.001 7.2 0.04 2.2 0.08
Waist-to-hip ratio
c 10.6 0.03 2.0 0.52 2.2 0.05
Physical activity, MET-hours per wk  2.4 0.58  4.4 0.12  2.4 0.03
Pack-years of smoking 11.0 0.03 8.1 0.02 0.6 0.59
Alcohol consumption, g per day 3.0 0.54 2.6 0.42  1.7 0.15
Regular aspirin/NSAID use 10.3 0.27 5.4 0.37 0.4 0.84
Abbreviations: BMI¼body mass index; CRP¼C-reactive protein; IL-6¼interleukin-6; MET¼metabolic equivalent¼(caloric need per kilogram body weight per hour activity)/(caloric need per
kilogram body weight per hour at rest); NSAID¼non-steroidal anti-inflammatory drug; sTNFR-2¼soluble tumour necrosis factor receptor 2.
aMultivariate linear models based on natural log-transformed biomarker levels included age (continuous, year), BMI (continuous, kgm
 2), physical activity(continuous, MET-hours per week),
pack-years of smoking (continuous), alcohol consumption (continuous, g per day), regular aspirin/NSAID use (X2 tablets per week, yes or no), regular use of multivitamins (yes or no), and
energy-adjusted intake of total fiber, saturated fat, monounsaturated fat, polyunsaturated fat and trans-fat (tertiles, g per day).
bPercentages of changes for one-s.d. increment of continuous variables (the s.d. of variables can be found in Table 1). For aspirin/NSAID use, percent of change of biomarker levels was
calculated for regular users relative to non-users.
cNinety one control participants with missing information on waist circumference and waist-to-hip ratio were excluded from the analysis, and BMI was excluded from the multivariate models.
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et al, 2006; Otani et al, 2006; Aleksandrova et al, 2010; Chan et al,
2011). These inconsistent results could be due to several possible
explanations. First, some results demonstrating an association
between inflammatory markers and CRC may be related to reverse
causation due to clinically undetected neoplasia at the time of
blood collection. Tumour cells can produce inflammatory cytokines
and induce surrounding tissue inflammation (Balkwill & Mantovani,
2001; Heikkila et al, 2007) and inflammatory markers can be
indicators of the host immune response to tumour antigens
(Coussens and Werb, 2002; Heikkila et al, 2007). Moreover, because
colorectal carcinogenesis is characterised by a relatively slow and
stepwise progression from normal to dysplastic epithelium to
carcinoma, which may take years or even decades, studies of
inflammatory markers in relation to incident CRC may be
particularly susceptible to reverse causation due to occult neoplasia
(Leslie et al, 2002). Similar to our results, several large prospective
studies, including the CLUE II cohort (Erlinger et al, 2004),
Women’s Health Study (Zhang et al, 2005), and the Rotterdam Study
(Siemes et al, 2006), have shown that exclusion of cases diagnosed in
the first years of blood collection attenuated the associations between
baseline CRP and subsequent development of CRC.
Second, inadequate control for potential confounders may
influence the findings of prior studies. Obesity, physical activity,
Table 3. Relative risk of CRC according to plasma inflammatory markers
Quartilea
Analyte 1 2 3 4 Ptrend
b
CRP
Median (mgl
 1) 0.38 0.79 1.49 3.44
No. of cases/controls 62/131 53/133 73/135 86/133
Crude RR (95% CI)
c 1.00 (reference) 0.86 (0.55–1.33) 1.14 (0.75–1.73) 1.38 (0.90–2.09) 0.04
Multivariate RR (95% CI)
d 1.00 (reference) 0.80 (0.51–1.26) 1.07 (0.69–1.64) 1.24 (0.80–1.93) 0.11
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.78 (0.50–1.24) 0.91 (0.58–1.41) 1.17 (0.74–1.83) 0.18
Within 2 years of follow-up
No. of cases/controls 7/24 3/11 8/20 24/27
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 1.18 (0.21–6.67) 1.04 (0.23–4.65) 4.73 (1.31–17.1) 0.005
After 2 years of follow-up
No. of cases/controls 55/107 50/122 65/115 62/106
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.76 (0.47–1.23) 0.87 (0.53–1.40) 0.90 (0.54–1.52) 0.91
IL-6
Median (pgml
 1) 0.73 1.15 1.64 3.42
No. of cases/controls 54/133 57/132 74/134 89/133
Crude RR (95% CI)
c 1.00 (reference) 1.10 (0.71–1.73) 1.44 (0.93–2.23) 1.70 (1.12–2.59) 0.01
Multivariate RR (95% CI)
d 1.00 (reference) 1.06 (0.67–1.68) 1.34 (0.85–2.11) 1.62 (1.05–2.50) 0.02
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.99 (0.61–1.59) 1.17 (0.74–1.87) 1.54 (0.99–2.40) 0.02
Within 2 years of follow-up
No. of cases/controls 3/16 5/23 15/22 19/21
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 1.30 (0.22–7.65) 6.27 (1.21–32.63) 6.78 (1.36–33.8) 0.01
After 2 years of follow-up
No. of cases/controls 51/117 52/109 59/112 70/112
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.96 (0.58–1.59) 0.94 (0.57–1.56) 1.26 (0.78–2.05) 0.21
sTNFR-2
Median (pgml
 1) 2108 2535 2999 3765
No. of cases/controls 68/133 66/133 78/133 62/133
Crude RR (95% CI)
c 1.00 (reference) 1.01 (0.66–1.53) 1.15 (0.76–1.76) 0.91 (0.58–1.45) 0.77
Multivariate RR (95% CI)
d 1.00 (reference) 1.01 (0.66–1.56) 1.15 (0.74–1.79) 0.97 (0.60–1.57) 0.97
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.92 (0.59–1.43) 1.07 (0.68–1.68) 0.87 (0.54–1.43) 0.69
Within 2 years of follow-up
No. of cases/controls 5/15 14/16 14/26 9/25
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 3.00 (0.67–13.48) 1.96 (0.45–8.61) 1.69 (0.29–9.77) 0.96
After 2 years of follow-up
No. of cases/controls 63/118 52/117 64/107 53/108
Multivariate RR (95% CI)
dþBMI (kgm
 2) 1.00 (reference) 0.80 (0.49–1.29) 1.00 (0.62–1.63) 0.89 (0.52–1.51) 0.83
Abbreviations: BMI¼body mass index; CI¼confidence interval; CRC¼colorectal cancer; CRP¼C-reactive protein; IL-6¼interleukin-6; RR¼relative risk; sTNFR-2¼soluble tumour necrosis
factor receptor 2.
aQuartiles of plasma inflammatory markers were based on the distribution among the control participants.
bTests for linear trend were conducted using the median values for each quartile of analyte.
cResults were based on conditional logistic regression. Controls were matched to cases on age and date of blood collection.
dResults were based on conditional logistic regression (matched for age and date of blood collection) with adjustment for CRC in parent or sibling (yes or no), prior lower gastrointestinal
endoscopy (yes or no), pack-years of smoking (continuous), alcohol consumption (continuous, g per day), physical activity (continuous, MET hours per week), regular aspirin/NSAID use (yes or
no, X2 tablets per week), regular use of multivitamins (yes or no), energy-adjusted intake of folate (including supplements, mg per day, continuous), calcium (including supplements, mg per day,
continuous) and total fiber (continuous, g per day), and red meat intake (continuous, serving per day).
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inflammatory activity and risk of CRC (Pischon et al, 2003a;
Chan and Giovannucci, 2010; Khandekar et al, 2011). However,
prior studies have had varying ability to account for these key
factors. For example, previous studies have been unable to adjust
for obesity (Il’yasova et al, 2005), physical activity (Erlinger et al,
2004; Il’yasova et al, 2005; Gunter et al, 2006) or aspirin/NSAID
use (Il’yasova et al, 2005; Aleksandrova et al, 2010). In the present
study, we found our multivariate RRs were substantially attenuated
compared with our unadjusted risk estimates, including an
association between CRP and CRC, which was no longer
significant after multivariate adjustment.
Third, heterogeneity in the study populations may account for
differing results. For example, the ATBC Study, which did observe
a significant association between CRP and CRC risk, entirely
comprised male smokers (Gunter et al, 2006). Compared with our
cohort, the median and interquartile range of CRP levels among
control men in the ATBC study (2.6mgl
 1, 1.4–4.8mgl
 1) were
approximately twice as high as those among control men in our
present study (1.11mgl
 1, 0.59–2.18mgl
 1), although the effects
of different sample sources and assays could not be excluded. In a
separate study of a parallel cohort of women, we did observe a
significant association between sTNFR-2, but not CRP or IL-6, and
risk of CRC (Chan et al, 2011). These contrasting results compared
with our findings suggest the possibility that the relationship
between inflammatory markers and CRC may vary according to
patient characteristics, such as smoking status or sex.
Although we did not observe a significant overall association
between inflammatory markers and risk of CRC after excluding
cases within 2 years of blood collection, we did observe a significant
relationship between IL-6 and risk of CRC, which appeared to vary
according to BMI. Among men with BMI o25kgm
 2, plasma
IL-6 was associated with increased risk of CRC. In contrast, among
men with BMI X25kgm
 2, IL-6 was not associated with CRC.
Recently, chronic inflammation has been implicated as a potential
mechanism that mediates the link between obesity and CRC
(Khandekar et al, 2011). A possible explanation for this observation
may be that inflammation-related mechanisms of colorectal
carcinogenesis predominate in lean men compared with over-
weight/obese men for whom other adiposity-related aetiological
exposures, such as insulin resistance, hyperinsulinaemia, or
dysregulated production of sex steroids (Giovannucci, 2001; Calle
and Kaaks, 2004), may be more evident. In support of this
explanation, previous studies have demonstrated that two other
aetiological pathways for CRC, including the IGF-I axis (for
example, IGF-I, IGF-I/IGFBP-3 ratio) and low vitamin D concen-
tration, were also associated with CRC development, primarily
among leaner individuals (Ma et al, 2004; Wei et al, 2005; Wu et al,
2007). Alternatively, we hypothesise that compared with overweight
men, who demonstrate substantial inflammation in adipose tissues
(Khandekar et al, 2011), high IL-6 levels in lean men may be more
reflective of localised inflammatory events in the colon, which are
more relevant to CRC development and can thus confer a greater
risk of CRC. In addition, Gunter et al (2006) also reported that CRP
was more strongly associated with CRC risk among male smokers
with a lower BMI in the ATBC cohort. Thus, further studies
examining potential mechanisms for the differential associations of
inflammatory markers with CRC according to BMI are needed.
Our study has several important strengths. First, our study was
prospective with a high follow-up rate. Second, we had detailed
information on lifestyle, dietary intake, and medication use, which
allowed us to adjust for potential confounding and evaluate
possible effect modification. Third, the complete ascertainment of
various diseases in this study population enabled us to exclude the
potential influence of other illnesses that might be related to both
inflammation and CRC, including diabetes mellitus and coronary
heart disease.
Our study also has some limitations. First, a single measurement
of plasma markers might have caused regression dilution bias
(Clarke et al, 1999) and precluded us from evaluating associations
between the long-term levels of these cytokines and risk of CRC.
However, these markers have been shown to be generally stable
over time (Pischon et al, 2003b; Platz et al, 2010). Second,
systematic inflammatory markers in plasma might not reflect the
tissue-specific inflammatory pathways most relevant to colorectal
carcinogenesis. Third, the results mainly from white men may not
be generalisable to other populations.
In conclusion, our findings do not appear to support a significant
association between plasma inflammatory markers and subsequent
risk of CRC among apparently healthy men. However, the
possibility that plasma IL-6 may be associated with an increased
risk of CRC in lean men requires further investigation.
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